Huanan C, Sangsang L, Amoah AN, Yacong B, Xuejiao C, Zhan S, et al. Relationship between triglyceride glucose index and the incidence of non-alcoholic fatty liver disease in the elderly: a retrospective cohort study in China. BMJ Open. 2020;10(11):e039804. https://doi.org/10.1136/bmjopen-2020-039804.
Li Y, Zheng R, Li J, Feng S, Wang L, Huang Z. Association between triglyceride glucose-body mass index and non-alcoholic fatty liver disease in the non-obese Chinese population with normal blood lipid levels: a secondary analysis based on a prospective cohort study. Lipids Health Dis. 2020;19(1):229. https://doi.org/10.1186/s12944-020-01409-1.
Yu Y, Cai J, She Z, Li H. Insights into the epidemiology, pathogenesis, and therapeutics of nonalcoholic fatty liver diseases. Adv Sci (Weinh). 2019;6(4):1801585. https://doi.org/10.1002/advs.201801585.
Kahn HS. The “lipid accumulation product” performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord. 2005;5(1):26. https://doi.org/10.1186/1471-2261-5-26.
Ding YS, Li Y, Zhang XH, Ma RL, Guo H, Ma L, et al. The improved lipid accumulation product is an accurate index for predicting metabolic syndrome in the Xinjiang population. Biomed Environ Sci. 2021;34(6):503–7. https://doi.org/10.3967/bes2021.070.
Dong L, Lin M, Wang W, Ma D, Chen Y, Su W, et al. Lipid accumulation product (LAP) was independently associatedwith obstructive sleep apnea in patients with type 2 diabetes mellitus. BMC Endocr Disord. 2020;20(1):179. https://doi.org/10.1186/s12902-020-00661-x.
Lee HJ, Jo HN, Kim YH, Kim SC, Joo JK, Lee KS. Predictive value of lipid accumulation product, fatty liver index, visceral adiposity index for metabolic syndrome according to menopausal status. Metab Syndr Relat Disord. 2018;16(9):477–82. https://doi.org/10.1089/met.2018.0019.
Mazidi M, Kengne AP, Katsiki N, Mikhailidis DP, Banach M. Lipid accumulation product and triglycerides/glucose index are useful predictors of insulin resistance. J Diabetes Complicat. 2018;32(3):266–70. https://doi.org/10.1016/j.jdiacomp.2017.10.007.
Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology. 2019;70(4):1457–69. https://doi.org/10.1002/hep.30626.
Wakabayashi I, Daimon T. The “cardiometabolic index” as a new marker determined by adiposity and blood lipids for discrimination of diabetes mellitus. Clin Chim Acta. 2015;438:274–8. https://doi.org/10.1016/j.cca.2014.08.042.
Shi WR, Wang HY, Chen S, Guo XF, Li Z, Sun YX. Estimate of prevalent diabetes from cardiometabolic index in general Chinese population: a community-based study. Lipids Health Dis. 2018;17(1):236. https://doi.org/10.1186/s12944-018-0886-2.
Wang H, Chen Y, Sun G, Jia P, Qian H, Sun Y. Validity of cardiometabolic index, lipid accumulation product, and body adiposity index in predicting the risk of hypertension in Chinese population. Postgrad Med. 2018;130(3):325–33. https://doi.org/10.1080/00325481.2018.1444901.
Wang H, Sun Y, Wang S, Qian H, Jia P, Chen Y, et al. Body adiposity index, lipid accumulation product, and cardiometabolic index reveal the contribution of adiposity phenotypes in the risk of hyperuricemia among Chinese rural population. Clin Rheumatol. 2018;37(8):2221–31. https://doi.org/10.1007/s10067-018-4143-x.
Wang H, Chen Y, Guo X, Chang Y, Sun Y. Usefulness of cardiometabolic index for the estimation of ischemic stroke risk among general population in rural China. Postgrad Med. 2017;129(8):834–41. https://doi.org/10.1080/00325481.2017.1375714.
Wang H, Sun Y, Li Z, Guo X, Chen S, Ye N, et al. Gender-specific contribution of cardiometabolic index and lipid accumulation product to left ventricular geometry change in general population of rural China. BMC Cardiovasc Disord. 2018;18(1):62. https://doi.org/10.1186/s12872-018-0798-0.
Wakabayashi I, Marumo M, Kubota Y, Higashiyama A, Miyamoto Y, Okamura T. Cardiometabolic index as a useful discriminator for the risk of increased arterial stiffness. Clin Chim Acta. 2018;486:42–3. https://doi.org/10.1016/j.cca.2018.07.017.
Farrell GC, Chitturi S, Lau GK, Sollano JD. Asia-Pacific working party on N. guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol. 2007;22(6):775–7. https://doi.org/10.1111/j.1440-1746.2007.05002.x.
Kaplan RC, Baldoni PL, Strizich GM, Perez-Stable EJ, Saccone NL, Peralta CA, et al. Current smoking raises risk of incident hypertension: Hispanic community health study-study of Latinos. Am J Hypertens. 2021;34(2):190–7. https://doi.org/10.1093/ajh/hpaa152.
Rominger C, Papousek I, Fink A, Perchtold CM, Lackner HK, Weiss EM, et al. Creative challenge: regular exercising moderates the association between task-related heart rate variability changes and individual differences in originality. PLoS One. 2019;14(7):e0220205. https://doi.org/10.1371/journal.pone.0220205.
Barton M. Cholesterol and atherosclerosis: modulation by oestrogen. Curr Opin Lipidol. 2013;24(3):214–20. https://doi.org/10.1097/MOL.0b013e3283613a94.
Kahn HS. The lipid accumulation product is better than BMI for identifying diabetes: a population-based comparison. Diabetes Care. 2006;29(1):151–3. https://doi.org/10.2337/diacare.29.1.151.
Nascimento-Ferreira MV, Rendo-Urteaga T, Vilanova-Campelo RC, Carvalho HB, da Paz OG, Paes Landim MB, et al. The lipid accumulation product is a powerful tool to predict metabolic syndrome in undiagnosed Brazilian adults. Clin Nutr. 2017;36(6):1693–700. https://doi.org/10.1016/j.clnu.2016.12.020.
Karatas S, Beysel S. Visceral adiposity index, triglyceride/high-density lipoprotein ratio, and lipid accumulation product index to discriminate metabolic syndrome among adult type 1 diabetes patients. Metab Syndr Relat Disord. 2021;19(9):507–12. https://doi.org/10.1089/met.2021.0047.
Dai H, Wang W, Chen R, Chen Z, Lu Y, Yuan H. Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults. Nutr Metab (Lond). 2017;14:49. https://doi.org/10.1186/s12986-017-0206-2.
Tantanavipas S, Vallibhakara O, Sobhonslidsuk A, Phongkitkarun S, Vallibhakara SA, Promson K, et al. Abdominal obesity as a predictive factor of nonalcoholic fatty liver disease assessed by ultrasonography and transient Elastography in polycystic ovary syndrome and healthy women. Biomed Res Int. 2019;9047324. https://doi.org/10.1155/2019/9047324.
Silaghi CA, Silaghi H, Craciun AE, Farcas A, Colosi HA, Cosma DT, et al. Age, abdominal obesity, and glycated hemoglobin are associated with carotid atherosclerosis in type 2 diabetes patients with nonalcoholic fatty liver disease. Med Ultrason. 2015;17(3):300–7. https://doi.org/10.11152/mu.2013.2066.173.cas.
Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6(10):772–83. https://doi.org/10.1038/nri1937.
Antraco VJ, Hirata BKS, de Jesus Simao J, Cruz MM, da Silva VS, da Cunha de Sa RDC, Abdala FM, Armelin-Correa L, Alonso-Vale MIC.Omega-3 Polyunsaturated Fatty Acids Prevent Nonalcoholic Steatohepatitis (NASH) and Stimulate Adipogenesis. Nutrients. 2021;13(2):622. https://doi.org/10.3390/nu13020622.
Lin IT, Lee MY, Wang CW, Wu DW, Chen SC. Gender differences in the relationships among metabolic syndrome and various obesity-related indices with nonalcoholic fatty liver disease in a Taiwanese population. Int J Environ Res Public Health. 2021;18(3):857. https://doi.org/10.3390/ijerph18030857.
Yang Y, Wang B, Yuan H, Li X, Mg KB. Triglycerides to High-Density Lipoprotein Cholesterol Ratio Is the Best Surrogate Marker for Insulin Resistance in Nonobese Middle-Aged and Elderly Population: A Cross-Sectional Study. Int J Endocrinol. 2021;2021:6676569. https://doi.org/10.1155/2021/6676569.
Quispe R, Martin SS, Jones SR. Triglycerides to high-density lipoprotein-cholesterol ratio, glycemic control and cardiovascular risk in obese patients with type 2 diabetes. Curr Opin Endocrinol Diabetes Obes. 2016;23(2):150–6. https://doi.org/10.1097/MED.0000000000000241.
Fan N, Peng L, Xia Z, Zhang L, Song Z, Wang Y, et al. Triglycerides to high-density lipoprotein cholesterol ratio as a surrogate for nonalcoholic fatty liver disease: a cross-sectional study. Lipids Health Dis. 2019;18(1):39. https://doi.org/10.1186/s12944-019-0986-7.
Lonardo A, Leoni S, Alswat KA, Fouad Y. History of nonalcoholic fatty liver disease. Int J Mol Sci. 2020;21(16):5888. https://doi.org/10.3390/ijms21165888.
Armandi A, Rosso C, Caviglia GP, Bugianesi E. Insulin resistance across the Spectrum of nonalcoholic fatty liver disease. Metabolites. 2021;11(3):155. https://doi.org/10.3390/metabo11030155.
Kitade H, Chen G, Ni Y, Ota T. Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments. Nutrients. 2017;9(4):387. https://doi.org/10.3390/nu9040387.
Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5(5):1544–60. https://doi.org/10.3390/nu5051544.
Xin Y, Wang Y, Chi J, Zhu X, Zhao H, Zhao S, et al. Elevated free fatty acid level is associated with insulin-resistant state in nondiabetic Chinese people. Diabetes Metab Syndr Obes. 2019;12:139–47. https://doi.org/10.2147/DMSO.S186505.
Medina-Urrutia A, Posadas-Romero C, Posadas-Sanchez R, Jorge-Galarza E, Villarreal-Molina T, Gonzalez-Salazar Mdel C, et al. Role of adiponectin and free fatty acids on the association between abdominal visceral fat and insulin resistance. Cardiovasc Diabetol. 2015;14(1):20. https://doi.org/10.1186/s12933-015-0184-5.
Sparks JD, Sparks CE, Adeli K. Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2012;32(9):2104–12. https://doi.org/10.1161/ATVBAHA.111.241463.
Choi SH, Ginsberg HN. Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol Metab. 2011;22(9):353–63. https://doi.org/10.1016/j.tem.2011.04.007.
Zhang S, Du T, Zhang J, Lu H, Lin X, Xie J, et al. The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease. Lipids Health Dis. 2017;16(1):15. https://doi.org/10.1186/s12944-017-0409-6.
Berk PD, Verna EC. Nonalcoholic fatty liver disease: lipids and insulin resistance. Clin Liver Dis. 2016;20(2):245–62. https://doi.org/10.1016/j.cld.2015.10.007.
Ballestri S, Nascimbeni F, Romagnoli D, Lonardo A. The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol Res. 2016;46(11):1074–87. https://doi.org/10.1111/hepr.12656.
Makaridze Z, Giorgadze E, Asatiani K. Association of the apolipoprotein b/apolipoprotein a-I ratio, metabolic syndrome components, total cholesterol, and low-density lipoprotein cholesterol with insulin resistance in the population of georgia. Int J Endocrinol. 2014;2014:925650. https://doi.org/10.1155/2014/925650.
Ballestri S, Mantovani A, Byrne CD, Lonardo A, Targher G. Diagnostic accuracy of ultrasonography for the detection of hepatic steatosis: an updated meta-analysis of observational studies. Metab Target Organ Damage. 2021;1:7. https://doi.org/10.20517/mtod.2021.05.
Farrell GC, Chitturi S, Lau GK, Sollano JD. Asia-Pacific working party on NAFLD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia–Pacific region: executive summary. J Gastroenterol Hepatol. 2007;22(6):775–7. https://doi.org/10.1111/j.1440-1746.2007.05002.x.
Schattenberg JM, Anstee QM, Caussy C, Bugianesi E, Popovic B. Differences between current clinical guidelines for screening, diagnosis and management of non-alcoholic fatty liver disease and real-world practice: a targeted literature review. Expert Rev Gastroenterol Hepatol. 2021;15(11):1253–66. https://doi.org/10.1080/17474124.2021.1974295.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.